Compared side by side

Retatrutide vs cagrilintide: how they differ

Reviewed How we check the libraryPublished by PepVault

The short answer

They act on different hormones: retatrutide activates three receptors, GLP-1, GIP and glucagon, while cagrilintide is a long-acting analogue of amylin, the fullness hormone the pancreas releases with insulin. Neither is approved; cagrilintide is the amylin half of Novo Nordisk’s CagriSema, and the crowd mostly runs it beside a GLP-1 drug such as retatrutide. Both are weekly shots, with half-lives of about 6 days for retatrutide and about a week for cagrilintide.

Side by side

ComparedRetatrutideCagrilintide
CategoryMetabolic & GLP-1Metabolic & GLP-1
Also known asLY3437943Cagri, AM833, NNC0174-0833
What it isThe first triple agonist to reach phase 3: it activates GLP-1, GIP and glucagon receptors at once, and the glucagon arm adds extra calorie burn (shown in mice).A long-acting version of amylin, the fullness hormone the pancreas releases alongside insulin, given as a weekly shot.
How it worksTriple GIP/GLP-1/glucagon receptor agonist. Produces large weight loss through appetite suppression and improved metabolic function; the glucagon arm adds energy expenditure, shown so far in mice. Its trials step the dose up every 4 weeks because GI side effects rise with the dose; in phase 2 they were milder with a 2 mg start than a 4 mg one.Long-acting, lipidated analogue of amylin, the satiety hormone the pancreas releases with insulin. It activates amylin receptors and the calcitonin receptor (a non-selective amylin agonist); amylin promotes fullness, slows stomach emptying and holds back glucagon after meals. A fatty-acid chain stretches its half-life to about a week, so it is a weekly shot, usually run beside a GLP-1. Not approved on its own: it is the amylin half of Novo Nordisk's CagriSema.
Commonly reportedAppetite suppression even stronger than tirzepatide, GI side effects after each step-up, and a higher resting heart rate. Its top dose averaged about 25–28% weight loss at 80 weeks in phase 3; it isn't approved yet.Feeling full sooner and portions shrinking, with nausea or constipation after step-ups and some injection-site reactions. It is not approved on its own.
Studied rangeResearch range: 1–12 mg, starting dose 2 mg. Studied in research — not a recommendation.Research range: 0.25–2.4 mg, starting dose 0.25 mg. Studied in research — not a recommendation.
How oftenWeeklyWeekly
Half-life~6 days (measured in early trials in people)~1 week (measured in people: 159–195 hours in a phase 1b trial)
RouteSubQ injectionSubQ injection
Typical runPhase 3 trials use continuous dosing. Community mirrors this — long-term with slow titration.Trials run it continuously: 26 weeks in phase 2, 68 weeks in phase 3. Community use is mostly as a weekly add-on to a GLP-1.
EvidenceEstablished: clinical trials or FDA-approved use existsEstablished: clinical trials or FDA-approved use exists
Common side effectsNausea, vomiting, diarrhea, constipation, decreased appetite, fatigue, abdominal painNausea, constipation, diarrhea, injection-site reactions

Typical run: Community practice — opinions vary. Not a clinical recommendation.

A smiling man in a grey t-shirt in his living room, holding his phone

Model. Individual results vary.

PepVault for iPhone

Taking retatrutide or cagrilintide? Log it in PepVault

Each dose, each vial and your step-ups in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Week by week

Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.

Retatrutide

  • Day 1–28 · 2 mg Triple-agonist is kicking in
  • Day 29–84 · 4 mg Dose-response steepens
  • Day 60+ · 9 mg Watch for dysesthesia at higher doses
  • Day 84+ This is a maintenance medication, not a course
  • Day 85–168 · 8 mg Higher steps: strong satiety
  • Day 169–336 No plateau yet at week 48
  • Day 337–476 Phase 3 territory: the headline numbers

Every card for retatrutide, with its sources

Cagrilintide

  • Day 1–28 · 0.25 mg The 0.25 mg start
  • Day 29–364 · 0.5 mg 0.5 mg, the second step
  • Day 57–364 · 1 mg 1 mg, the middle step
  • Day 85–364 · 1.7 mg 1.7 mg, the step before 2.4 mg
  • Day 113+ · 2.4 mg 2.4 mg, the phase 3 dose

Every card for cagrilintide, with its sources

Together or one or the other

Retatrutide and cagrilintide are a common stack: cagrilintide lists retatrutide among its common stacks.

Animal · Cagrilintide

With retatrutide or tirzepatide: the crowd's stacks

Cagrilintide beside retatrutide or tirzepatide is a common crowd stack, on the same logic as CagriSema. No trial in people has tested these pairs; in obese rats, cagrilintide plus retatrutide lost more weight than either alone.

Questions people ask

How long do retatrutide and cagrilintide last?

The half-life of retatrutide is ~6 days (measured in early trials in people). The half-life of cagrilintide is ~1 week (measured in people: 159–195 hours in a phase 1b trial).

How often are retatrutide and cagrilintide taken?

Retatrutide: weekly. Route: SubQ injection. Cagrilintide: weekly. Route: SubQ injection.

How are retatrutide and cagrilintide dosed in research?

The research range for retatrutide is 1–12 mg, with a 2 mg starting dose. The research range for cagrilintide is 0.25–2.4 mg, with a 0.25 mg starting dose. Studied in research — not a recommendation.

What are the common side effects of retatrutide and cagrilintide?

For retatrutide, the library lists: nausea, vomiting, diarrhea, constipation, decreased appetite, fatigue, abdominal pain. For cagrilintide: nausea, constipation, diarrhea, injection-site reactions.

Are retatrutide and cagrilintide taken together?

Retatrutide and cagrilintide are a common stack: cagrilintide lists retatrutide among its common stacks. Cagrilintide beside retatrutide or tirzepatide is a common crowd stack, on the same logic as CagriSema. No trial in people has tested these pairs; in obese rats, cagrilintide plus retatrutide lost more weight than either alone.

Each one in full

Track it in the app

PepVault for iPhone

Taking retatrutide or cagrilintide? Log it in PepVault

Each dose, each vial and your step-ups in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo